Współczesna Onkologia

Abstract

3/2019 vol. 23
Original paper

Evaluation of oxaliplatin-induced pulmonary toxicity in rats

  1. Department of Chest Diseases, Faculty of Medicine, Sitki Kocman University, Mugla, Turkey
  2. Department of Medical Oncology, Faculty of Medicine, Sitki Kocman University, Mugla, Turkey
  3. Department of Chest Diseases, Sağlık Bilimleri University, Yüksek İhtisas Education and Research Hospital, Bursa, Turkey
  4. Department of Medical Biochemistry, Faculty of Medicine, Katip Celebi University, Izmir, Turkey
  5. Department of Pathology, Faculty of Medicine, Sitki Kocman University, Mugla, Turkey
  6. Department of Medical Oncology, Faculty of Medicine, Adnan Menderes University, Aydın, Turkey
  7. Department of Thoracic Surgery, Faculty of Medicine, Sitki Kocman University, Mugla, Turkey
  8. Department of Medical Pharmacology, Faculty of Medicine, Adnan Menderes University, Aydın, Turkey
Contemp Oncol (Pozn) 2019; 23 (3): 151-156
Online publish date: 2019/10/31
View full text
Confronting perimenopausal women’s knowledge of coronary heart disease with their health behaviours. Controversial role of hormone replacement therapy in the protection of coronary heart disease

Introduction

The mechanism of oxaliplatin (OXA) induced pulmonary toxicity is not fully understood.

Aim of the study

The present study was designed to investigate the pulmonary toxicity of OXA that has been reported in previous studies. Study design: animal experiments.

Material and methods

A total of 40 female Wistar rats were divided into 5 groups. In group 1, 5% glucose was injected intra-peritoneally; then the rats were sacrificed on day 14. OXA was administered in groups 2, 3, 4, and 5; then the animals were sacrificed on day 7 in group 2, day 14 in group 3, day 28 in group 4 and day 48 in group 5. The groups were further categorized as short-term administration and long-term administration groups. Furthermore, tissue glutathione peroxidase (GPX) activity was measured in all rats.

Results

The mean GPX activities were 0.66 U/mg in the sham group, 0.74 U/mg in the short-term groups, and 0.74 U/mg in the long-term groups. We found that long-term OXA administration causes pulmonary toxicity resulting in increased intra-alveolar/interstitial macrophages and interstitial pneumonia. Similarly, we found reduced and permanent tissue GPX activity in rats that received OXA in higher doses and for a long term.

Conclusions

Long-term OXA therapy causes toxic changes in the lung tissue.

Share
without publication fees